Kathy Lee-Sepsick, CEO at Femasys, discusses innovative advances in women's medical technology, focusing on improving accessibility and effectiveness of fertility treatments. They explore groundbreaking solutions for low sperm count cases and the challenges of navigating FDA approval. The podcast highlights the importance of data collection for successful commercial launch in the fertility technology market.
Read more
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
FEMASIS introduces innovative IUI method placing sperm directly in the fallopian tube, increasing conception chances.
FEMASIS offers affordable fertility treatments as an initial step before IVF, FDA clearance ensures safety.
Deep dives
FEMASIS Innovation in IUI
FEMASIS, a biomedical company, introduces a more effective method of intrauterine insemination (IUI) aimed at revolutionizing fertility treatments for women. Unlike traditional IUI methods, FEMASIS places sperm directly into the fallopian tube instead of the uterine cavity, increasing the chances of conception. The company's mission focuses on advancing medical technologies for underserved areas in women's health, with an emphasis on enhancing the natural fertilization process. FEMASIS' recent trial data showcased a 24% success rate in women with male factor infertility, proving the effectiveness of their approach.
Cost-Effectiveness and Accessibility of FEMASIS
FEMASIS offers an affordable and convenient alternative to in vitro fertilization (IVF) with a procedure cost in the range of a few thousand dollars, significantly lower than the average cost of IVF. Targeting a wide demographic, FEMASIS positions itself as an initial step before considering IVF, particularly for women without specific genetic disorders. The company's regulatory clearance from the FDA in September last year paves the way for accessible and safe fertility treatments for women and couples.
Differentiation and Safety of FEMASIS
FEMASIS distinguishes itself from other IUI methods by delivering sperm directly to the fallopian tube, optimizing the conception process and minimizing hostile uterine conditions for sperm. With minimal side effects such as cramping and spotting, FEMASIS' method is minimally invasive and ensures efficient sperm placement for increased success rates. By incorporating a unique balloon technology to guide sperm to the fallopian tube, FEMASIS sets a new standard in reproductive endocrinology, emphasizing simplicity and effectiveness.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. Kathy Lee-Sepsick, CEO at Femasys, discusses an accessible, safe, and cost-effective alternative to IVF. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.